Class II — Potential Health Hazard

Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

RANOLAZINE ER Tablet Recalled by Aidapak Services, LLC Due to Mislabeling

Date: July 2, 2013
Company: Aidapak Services, LLC
Status: Terminated
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Aidapak Services, LLC directly.

Affected Products

RANOLAZINE ER Tablet, 500 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 61958100301

Quantity: 840 Tablets

Why Was This Recalled?

Labeling:Label Mixup; RANOLAZINE ER Tablet, 500 mg may be potentially mislabeled as MELATONIN, Tablet, 3 mg, NDC 51991001406, Pedigree: AD25452_16, EXP: 5/3/2014; DULoxetine HCl DR, Capsule, 20 mg, NDC 00002323560, Pedigree: AD70585_16, EXP: 5/29/2014; OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 00904404360, Pedigree: W002852, EXP: 6/7/2014; VALSARTAN, Tablet, 80 mg, NDC 00078035834, Pedigree:

Where Was This Sold?

Repacked drugs were distributed in Arizona, California, Oregon, and Washington.

About Aidapak Services, LLC

Aidapak Services, LLC has 538 total recalls tracked by RecallDetector.

Related Recalls

Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...

Zydus Pharmaceuticals (USA) Inc · March 9, 2026

Class II — Potential Health Hazard

Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...

Rising Pharma Holding, Inc. · March 3, 2026

Class II — Potential Health Hazard

Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility

New Life Pharma LLC · February 26, 2026

Class II — Potential Health Hazard

Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility

New Life Pharma LLC · February 26, 2026

Class II — Potential Health Hazard

Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility

New Life Pharma LLC · February 26, 2026

Class II — Potential Health Hazard

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report